Efficacy of pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis

详细信息    查看全文

• 作者：Nicola Coppola (1)
  Mariantonietta Pisaturo (1)
  Gilda Tonziello (1)
  Caterina Sagnelli (4)
  Evangelista Sagnelli (1) (3)
  Italo F Angelillo (2)
  
• 关键词：Antiviral therapy in HCV patients ; Meta ; analysis ; Response to anti ; HCV therapy ; Tolerability of anti ; HCV therapy
• 刊名：BMC Infectious Diseases
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：12
• 期：1
• 全文大小：275KB
• 参考文献：1. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. / J Hepatol 2006, 45:529-38. CrossRef
  2. Ghany MG, Strader DB, Thomas DL, Seef IL: Diagnosis, management and treatment of hepatitis C: an update. / Hepatology 2009, 49:1335-374. CrossRef
  3. Practice guidelines for the treatment of hepatitis C: Practice guidelines for the treatment of hepatitis C: Recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. / Dig Liv Dis 2010, 42:81-1. CrossRef
  4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. / Lancet 2001, 358:958-65. CrossRef
  5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gon?ales FL Jr, H?ussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. / N Engl J Med 2002, 347:975-82. CrossRef
  6. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM: PEGASYS International Study Group Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. / Ann Intern Med 2004, 140:346-55.
  7. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. / Lancet 1999, 354:1896-900. CrossRef
  8. Jadad AR, Moore RA, Carrol D, Jenkinson C, Reynolds DJM, Gavalghon DJ: Assessing the quality of reports of randomized clinical trials. Is blinding necessary? / Control Clin Trials 1996, 17:1-2. CrossRef
  9. Chalmers TC, Smith H Jr, Blackburn B, Silverman B, Schroeder B, Reitman D: A method for assessing the quality of a randomized control trial. / Control Clin Trials 1981, 2:31-9. CrossRef
  10. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. / J Natl Cancer Inst 1959, 22:719-48.
  11. Der Simonian R, Laird N: Meta-analysis in clinical trials. / Control Clin Trials 1986, 7:177-88. CrossRef
  12. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. / Stat Med 2002, 21:1539-558. CrossRef
  13. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. / Biometrics 1994, 50:1088-099. CrossRef
  14. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. / BMJ 1997, 315:629-34. CrossRef
  15. Corporation S: / Stata Statistical Software: Release 10. TX, USA: College Station; 2010.
  16. Yenice N, Mehtap O, Gumrah M, Arican N: The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. / Turk J Gastroenterol 2006, 17:94-8.
  17. Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK: Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. / J Vir Hep 2007, 14:721-29.
  18. Escudero A, Rodríguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM: Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. / J Gastroenterol Hepatol 2008, 23:861-66. CrossRef
  19. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS: IDEAL Study Team Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. / N Engl J Med 2009, 361:580-93. CrossRef
  20. Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, Picciotto FP, Marino-Marsilia G, Fontanella L, Leandro G: Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. / Gastroenterology 2010, 138:116-22. CrossRef
  21. Lee S, Kim IH, Kim SH, Kim SW, Lee SO, Lee ST, Kim DG, Lee CS, Choi CS, Cho EY, Kim HC: Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients. / Intervirology 2010, 53:146-53. CrossRef
  22. Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R, Del Ninno E, Russo A, Colombo M: Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. / Gastroenterology 2010, 138:108-15. CrossRef
  23. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Abergel A, Pess?a MG, Lin A, Tietz A, Connell EV, Diago M: A Sustained Virologic Response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. / Gastroenterology 2010, 139:1593-601. CrossRef
  24. Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C: Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. / Hepatology 2010, 51:1176-184. CrossRef
  25. Zhao S, Liu E, Chen P, Cheng D, Lu S, Yu Q, Wang Y, Wei K, Yang P: A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: a meta-analysis of randomized trials. / Clin Ther 2010, 32:1565-577. CrossRef
  26. Taliani G, Gemignani G, Ferrari C, Aceti A, Bartolozzi D, Blanc PL, Capanni M, Esperti F, Forte P, Guadagnino V, Mari T, Marino N, Milani S, Pasquazzi C, Rosina F, Tacconi D, Toti M, Zignego AL, Messerini L, Stroffolini T: Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. / Gastroenterology 2006, 130:1098-106. CrossRef
  27. Torriani FJ, Rodriguez-Torris M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV infected patients. / N Engl J Med 2004, 351:438-50. CrossRef
  28. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C: Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. / N Engl J Med 2004, 351:451-59. CrossRef
  29. Hiramatsu N, Oze T, Yakushijin T, Inoue Y, Igura T, Mochizukiet K, Imanaka K, Kaneko A, Oshita M, Hagiwara H, Mita E, Nagase T, Ito T, Inui Y, Hijioka T, Katayama K, Tamura S, Yoshihara H, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa K, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N: Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. / J Vir Hep 2009, 16:586-94. CrossRef
  30. Jacobson IM, Brown RS, Freilich B, Afdhal N, Kwo PY, Santoro Y, Hargrave T, Kwo PY, Lambiase L, Galler GW, Araya V, Freilich B, Harvey J, Griffel LH, Brass CA: Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic Hepatitis C patients: a randomized trial. / Hepatology 2007, 46:971-81. CrossRef
  31. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/12/357/prepub
  
• 作者单位：Nicola Coppola (1)
  Mariantonietta Pisaturo (1)
  Gilda Tonziello (1)
  Caterina Sagnelli (4)
  Evangelista Sagnelli (1) (3)
  Italo F Angelillo (2)
  
  1. Department of Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy
  4. Department of Clinical and Experimental Medicine and Surgery, “F. Magrassi e A. Lanzara-Second University of Naples, Naples, Italy
  3. Division of Infectious Diseases, Azienda Ospedaliera Sant’Anna e San Sebastiano di Caserta, Caserta, Italy
  2. Department of Experimental Medicine, Section of Hygiene, Second University of Naples, Naples, Italy
  

文摘

Background Two formulations of Pegylated interferon (Peg-IFN) are on the market for treatment of chronic hepatitis C virus (HCV) infection. The purpose of this meta-analysis was to assess the efficacy of Peg-IFN α-2a versus Peg-IFN α-2b in combination with ribavirin in anti-human immunodeficiency virus (HIV)-negative patients with genotype 1 chronic HCV infection. Methods The following criteria were to be met for inclusion in the meta-analysis: (a) original data from randomized and non-randomized clinical trials; (b) study on the efficacy of conventional doses of Peg-IFN α-2a (180?μg/week) versus Peg-IFN α-2b (1.5?μg/kg of body weight/week), both in combination with ribavirin, in antiviral therapy-na?ve HCV-genotype 1 subjects; (c) at least one of these primary outcomes: Rapid Virological Response (RVR); Early Complete Virological Response (EVR); End of Treatment Response (ETR); Sustained Virological Response (SVR); (d) odds ratio estimates of relative risk (RR) and associated 95% confidence intervals (CIs) or at least data enabling them to be computed; (e) English language; and (f) published as a full paper up to December 2011. Results Seven published studies met the inclusion criteria, allowing a meta-analysis on 3,026 patients. Peg-IFN α-2a and Peg-IFN α-2b showed similar rate of RVR (RR--.05; 95% CI--.87-1.27, p--.62) and SVR (RR--.08; 95% CI--.99-1.18, p--.098). Peg-IFN α-2a more frequently than Peg-IFN α-2b achieved EVR (RR--.11; 95% CI--.02-1.21, p--.013) and ETR (RR--.22; 95% CI--.14-1.31, p-lt;-.0001). Conclusion The standard schedules of Peg-IFN α-2a and Peg-IFN α-2b, both in combination with ribavirin, can be used indifferently for patients with chronic HCV genotype 1 who are anti- to eliminate HIV-negative and antiviral treatment-na?ve.